-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Professor Xie Xiaoliang, Co-Founder of Danshu Biological and Chairman of the Scientific Advisory Committee, is a fellow of the American Academy of Sciences, a member of the American Academy of Medicine, and a foreign academician of the Chinese Academy of Sciences.
he was the founder of single-molecule enzymatics, one of the founders of single-molecule biophysical chemistry, and a pioneer in co-relevant Raman scattering microimaging technology and single-cell genomics.
Singlomics, co-founded by Professor Xie Xiaoliang, is committed to the research and development of antibody drugs using its world-leading single-cell sequencing technology platform, and continuously promotes innovative drug research for adaptations, including infectious and autoimmune diseases.
is preparing to build a production base for Changping antibody drugs in Beijing.
previously completed round A financing, it is understood that a leading pharmaceutical fund for its investors.
On August 27, 2020, Baiji Shenzhou and Beijing Danshu Bio announced that they have reached an exclusive licensing agreement that Baiji Shenzhou will develop, produce and commercialize Danshu Bio in the research of new coronavirus and antibodies, including DXP-593 and DXP-604, worldwide outside Greater China.
DXP-593 and DXP-604 are two new coronavirus-infested antibodies screened from more than 60 new coronary pneumonia rehabilitation antigen B cells using high-flung single-cell transcription groups and VDJ sequencing techniques.
DXP-593 showed strong median activity in the fake and new coronavirus, with semi-inhibitory concentrations of 1.2 ng/ml and 15 ng/ml, respectively.
DXP-593 also has strong efficacy and preventive effects in rodent models infected with the new coronavirus.
the DXP-604 binding table is different from the DXP593, but also has high school and activity.
DXP-593 and DXP-604 are expected to be cocktail therapy options to avoid resistance caused by viral mutations.
, a member of the Chinese Academy of Sciences, first participated in the creation of Baiji Shenzhou as a co-founder in 2010.
company is currently listed in both China and the United States, in research and development progress and foreign cooperation in the performance of bright.
2018, Dr. Zhang Zhiyuan, a senior research fellow/director of the Center for Technology Transformation at Beisheng University, co-founded Sironax, a global biopharmaceutical company focused on the development of First-in-class chemicals.
research and development of small molecule inhibitors for Wang Xiaodong academicians in the field of apoptosis, cell procedural necrosis and other cell death, dedicated to the treatment of a variety of major diseases.
These inhibitors target diseases such as neurodegenerative diseases such as Alzheimer's disease, multiple sclerosis, Parkinson's disease, ischemic diseases such as stroke, kidney ischemia, myocardial ischemia, and inflammatory diseases such as enteritis, psoriasis, sepsis, etc.
are RIP1, MLKL, and so on.
was founded, it was a huge investment in high-rise capital.
Shi Yigong as co-founder, and Dr. Cui Yusong co-founded No Cheng Jianhua in 2015;
focuses on the treatment of oncology and autoimmune diseases, and as of August 27, 2020, The Hong Kong stock is currently valued at approximately HK$17 billion.
important preclinical candidates are: small molecule TYK2 inhibitors, SHP2 destructive inhibitors, oral protein degradation small molecule new drugs.
Dong Chen academician Dong Chen founded Xinkang healing biopharmaceutical was founded in 2015, the company's research and development team relying on innovative antibody research and development related to the core technology platform, quickly promote the research products in progress, focusing on tumor immunity and autoimmune innovative antibody drug research and development.
Xinkang and Lizhu single anti-joint development of IL-17A/F single anti-is being carried out in China phase 1 clinical.
IL-17A and IL-17F exist in vivo in the form of yso-2000SIL-A and IL-17F-F, as well as heterogeneic djumer IL-17A-F.
these glymers act on the subjects IL-17RA and IL-17RC and promote other inflammatory cytokines such as IL-6, TNF alpha, IL-1 beta, IL-20 The expression of family cytokines, GM-CSFs, and effect proteins, and further lead to the activeness of neutral granulocytes and macrophages, as well as the cortical and fibroblasts, play an important role in the pathophysiology of many autoimmune diseases.
as of February 2020, recombinant anti-human IL-17A/F humanized monoclonal antibody injections have invested a cumulative total of RMB39.2376 million in research and development.
2020, Mr. Dong left Tsinghua University to join Renji Hospital, Shanghai Jiaoxuan University School of Medicine.
Rao Yi, president of the University of China, founded the former Kihuayi in August 2018, and the company is located in Zhongguancun Life Sciences Park.
company focuses on rhythm-regulating drugs, sleep-regulating drugs, gene therapy and other fields of product development, will be deeply cultivated in the field of neural research and development of new drugs and new technologies hatched.
the establishment of the Company, it has been invested by Huaxing Capital and Tencent.
.